Literature DB >> 8566753

Adenovirus replication is coupled with the dynamic properties of the PML nuclear structure.

V Doucas1, A M Ishov, A Romo, H Juguilon, M D Weitzman, R M Evans, G G Maul.   

Abstract

Wild-type PML and at least four other novel proteins are localized within discrete nuclear structures known as PODs. We demonstrate here that during adenovirus infection, immediate early viral proteins from the E1 and E4 transcription units associate with the POD, which in turn undergoes a dramatic morphological change. During this process, the auto-antigen Sp-100 and NDP55 but not PML, relocate from the POD to the viral inclusion bodies, the sites of adenovirus DNA replication and late RNA transcription. The E4-ORF3 11-kD protein alone will induce this reorganization and reciprocally, viruses carrying mutations in the E4-domain fail to do so. These same viral mutants are defective in viral replication as well as the accumulation of late viral mRNAs and host cell transcription shutoff. We show that interferon (INF) treatment enhances the expression of PML, reduces or blocks PODs reorganization, and inhibits BrdU incorporation into viral inclusion bodies. In addition, cell lines engineered to overexpress PML prevent PODs from viral-induced reorganization and block or severely delay adenovirus replication. These results suggest that viral replication relies on components of the POD and that the structure is a target of early viral proteins.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8566753     DOI: 10.1101/gad.10.2.196

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  156 in total

1.  E4ORF3 requirement for achieving long-term transgene expression from the cytomegalovirus promoter in adenovirus vectors.

Authors:  D Armentano; M P Smith; C C Sookdeo; J Zabner; M A Perricone; J A St George; S C Wadsworth; R J Gregory
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  Roles for the E4 orf6, orf3, and E1B 55-kilodalton proteins in cell cycle-independent adenovirus replication.

Authors:  F D Goodrum; D A Ornelles
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

3.  A role for the GSG domain in localizing Sam68 to novel nuclear structures in cancer cell lines.

Authors:  T Chen; F M Boisvert; D P Bazett-Jones; S Richard
Journal:  Mol Biol Cell       Date:  1999-09       Impact factor: 4.138

4.  "Hit-and-run" transformation by adenovirus oncogenes.

Authors:  M Nevels; B Täuber; T Spruss; H Wolf; T Dobner
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

5.  Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption.

Authors:  S Müller; A Dejean
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

6.  SUMO-1 modification required for transformation by adenovirus type 5 early region 1B 55-kDa oncoprotein.

Authors:  C Endter; J Kzhyshkowska; R Stauber; T Dobner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

7.  Functional analysis of adenovirus protein IX identifies domains involved in capsid stability, transcriptional activity, and nuclear reorganization.

Authors:  M Rosa-Calatrava; L Grave; F Puvion-Dutilleul; B Chatton; C Kedinger
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

8.  Cytoplasmic catalytic subunit of protein kinase A mediates cross-repression by NF-kappa B and the glucocorticoid receptor.

Authors:  V Doucas; Y Shi; S Miyamoto; A West; I Verma; R M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

Review 9.  Human pathogens and the host cell SUMOylation system.

Authors:  Peter Wimmer; Sabrina Schreiner; Thomas Dobner
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

Review 10.  A guide to viral inclusions, membrane rearrangements, factories, and viroplasm produced during virus replication.

Authors:  Christopher Netherton; Katy Moffat; Elizabeth Brooks; Thomas Wileman
Journal:  Adv Virus Res       Date:  2007       Impact factor: 9.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.